Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers

NCT07033585 · tracked via the Priya Life Science USA tracker

Sponsor

Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair

Phase

Phase 2/3

Started

2026-06-15

Last updated

2026-08-27

Condition(s) studied

Type 2 Diabetes

Investigational drug(s) / intervention(s)

Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetesChina Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes

Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes: Farxiga® (dapagliflozin) 10 mg, Onglyza® (saxagliptin) 5 mg, Metformin 500 mg, Oral Mix Prescription Treat type 2 diabetes patients with controlled cancers

China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes: China Import (dapagliflozin) 10 mg, China Import (saxagliptin) 5 mg, Metformin 500 mg, Oral Mix Prescription Treat type 2 diabetes patients with controlled cancers

Study summary

Use Dapagliflozin 10 mg, Saxagliptin 5 mg, Metformin 500 mg treat type 2 diabetes patients with controlled cancers

Eligibility

Sex

ALL

Min age

24 Years

Max age

64 Years

Healthy volunteers

* Select 600 type 2 diabetes patients with controlled cancers. * Dosage Duration at least 90 days Inclusion Criteria: * 1\. Clinical diagnosis of type 2 diabetes * 2\. Controlled cancers * 3\. Suitable for enough blood-drawing * 4\. Random and double blind * 5\. Measurable disease * 6\. Adequate organ functions * 7\. Adequate performance status * 8\. Age 24 years old and over * 9\. Sign an informed consent form * 10\. Receive blood-drawing Exclusion Criteria: * 1\. Uncontrolled cancers * 2\. Pregnancy * 3\. Breast-feeding * 4\. The patients with other serious intercurrent illness or infectious diseases * 5\. The participating patients have serious side effects. * 6\. Serious Allergy to Drugs * 7\. Thrombus or Bleed Tendency * 8\. Serious Risks or Serious Adverse Events of the drug product * 9\. The prohibition of drug products * 10\. Have no therapeutic effects

Primary outcome measure(s)

Detect Hemoglobin A1c (HbA1c) — Duration up to 90 days
Draw blood Detect Hemoglobin A1c (HbA1c)
Detect fasting blood glucose (FBG) — Duration up to 90 days
Draw blood Detect fasting blood glucose (FBG)
Detect 2-hour postprandial blood glucose (2 hPBG) — Duration up to 90 days
Draw blood Detect 2-hour postprandial blood glucose (2 hPBG)
Detect fasting insulin (FINS) — Duration up to 90 days
Draw blood Detect fasting insulin (FINS)
Detect 2-hour postprandial insulin (2 hPINS) — Duration up to 90 days
Draw blood Detect 2-hour postprandial insulin (2 hPINS)

Trial sites (1)

Facility	City	Region	Status
Medicine Invention Design, Inc. - IORG0007849 - NPI-1023387701	Rockville	Maryland

More Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair trials in the USA

Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms Active, not recruiting

Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms Active, not recruiting

Other trials for the same condition

A Study of PATAS Trifluoroacetate Using Single Ascending Doses in Healthy Volunteers Active, not recruiting

A Phase 1, Multiple Ascending Dose Study to Evaluate HMS1005 in Participants With Type 2 Diabetes Recruiting

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes Active, not recruiting

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight Recruiting

A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07033585 on ClinicalTrials.gov ↗ ← All trials in the USA